GSK 256066

Drug Profile

GSK 256066

Alternative Names: 256066; GSK256066

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Amides; Aminoquinolines; Antiallergics; Antiasthmatics; Phenyl ethers; Small molecules; Sulfones
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Seasonal allergic rhinitis

Most Recent Events

  • 31 Dec 2011 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Estonia, Finland, Germany, Netherlands, Russia and Slovakia (Inhalation)
  • 31 Dec 2009 Discontinued - Phase-II for Asthma in United Kingdom, New Zealand and South Africa (Inhalation)
  • 31 Dec 2008 Discontinued - Phase-II for Seasonal allergic rhinitis in Austria and Germany (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top